The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Background: Cardiomyopathies are a heterogeneous group of pathologies characterized by
structural and functional alterations of the heart. Aims: The purpose of this narrative review is …

Objectives This study examined fibrosis progression in hypertrophic cardiomyopathy (HCM)
patients, as well as its relationship to patient characteristics, clinical outcomes, and its effect …

Члены Рабочей группы подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Рабочей …

Guidelines Liaison; cHFSA Representative; dASE Representative; eHRS Representative;
fSCMR Representative; gAATS Representative; hSCAI Representative; and iFormer Joint …

: hypertrophic cardiomyopathy, obstructive hypertrophic cardiomyopathy, hypertrophic
cardiomyopathy phenocopies, sarcomeric mutations, familial genetic screening, sudden …

Abstract Aim The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the
Management of Hypertrophic Cardiomyopathy” provides recommendations to guide …

Objectives To examine the relationship between late gadolinium enhancement (LGE) extent
and nonsustained ventricular tachycardia (NSVT) characteristics in patients with …

Atrial fibrillation (AF) is common among patients with hypertrophic cardiomyopathy (HCM)
with a prevalence> 25%. AF in HCM is associated with a high risk of stroke and can be a …

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy,
presenting significant clinical heterogeneity. Arrhythmia risk stratification and detection are …